ShanXi C&Y Pharmaceutical GroupLTD Management
Management criteria checks 4/4
ShanXi C&Y Pharmaceutical GroupLTD's CEO is Qun Zhao, appointed in Oct 2021, has a tenure of 3.25 years. directly owns 5.51% of the company’s shares, worth CN¥113.02M. The average tenure of the management team and the board of directors is 7.4 years and 4.9 years respectively.
Key information
Qun Zhao
Chief executive officer
CN¥943.8k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.3yrs |
| CEO ownership | 5.5% |
| Management average tenure | 7.4yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Improved Revenues Required Before ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE:300254) Shares Find Their Feet
Sep 30
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues
May 27ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues
Mar 25ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Mar 06CEO
Qun Zhao (53 yo)
3.3yrs
Tenure
CN¥943,800
Compensation
Mr. Qun Zhao has been President of ShanXi C&Y Pharmaceutical Group Co., Ltd. since October 26, 2021 and its a Director since June 1, 2010. Mr. Zhao served as Chairman of the Board at ShanXi C&Y Pharmaceuti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | 3.3yrs | CN¥943.80k | 5.51% CN¥ 113.0m | |
| Financial Director | 6.3yrs | CN¥558.90k | no data | |
| Secretary | 8.5yrs | CN¥774.80k | 0.42% CN¥ 8.6m | |
| Chief Engineer | 8.5yrs | CN¥453.90k | 0.030% CN¥ 620.1k |
7.4yrs
Average Tenure
55yo
Average Age
Experienced Management: 300254's management team is seasoned and experienced (7.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | 14.6yrs | CN¥943.80k | 5.51% CN¥ 113.0m | |
| Secretary | 13yrs | CN¥774.80k | 0.42% CN¥ 8.6m | |
| Vice Chairman | 9.8yrs | CN¥668.30k | 1.03% CN¥ 21.1m | |
| Chairman | 4.9yrs | CN¥89.40k | 2.2% CN¥ 45.1m | |
| Independent Director | 4.9yrs | CN¥60.00k | no data | |
| Independent Director | 4.9yrs | CN¥60.00k | no data | |
| Supervisor | 14.6yrs | no data | no data | |
| Supervisor | 11.6yrs | no data | no data | |
| Supervisory Board Chairman | 1.9yrs | no data | 0.048% CN¥ 989.9k | |
| Independent Director | 2.3yrs | CN¥60.00k | no data | |
| Independent Director | 1.6yrs | CN¥30.00k | no data |
4.9yrs
Average Tenure
57yo
Average Age
Experienced Board: 300254's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 08:07 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ShanXi C&Y Pharmaceutical Group Co.,LTD. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Jun Ling | Ping An Securities Co. Ltd. |
| Xiao Peng | TX Investment Consulting Co., Ltd. |